In a report released today, Roanna Ruiz from Leerink Partners maintained a Buy rating on Aligos Therapeutics (ALGS – Research Report), with a price target of $10.00. The company’s shares closed last Tuesday at $2.64, close to its 52-week low of $2.47.
According to TipRanks.com, Ruiz has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -34.1% and a 18.8% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as Enanta Pharmaceuticals, Xeris Pharmaceuticals, and Atea Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aligos Therapeutics with a $14.67 average price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $35.00 and a one-year low of $2.47. Currently, Aligos Therapeutics has an average volume of 476.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH).
Read More on ALGS:
- Leerink Partners Reaffirms Their Buy Rating on Hookipa Pharma (HOOK)
- Leerink Partners Thinks Xeris Pharmaceuticals’ Stock is Going to Recover
- Myovant Sciences (MYOV) Receives a Hold from Leerink Partners
- ContraFect (CFRX) Receives a Buy from Leerink Partners
- Telsey Advisory Maintains a Hold Rating on Wolverine World Wide (WWW)
